HIV-associated talaromycosis
Conditions
Interventions
single high-dose L-AmB group:single high-dose L-AmB
control group:amphotericin B deoxycholate(AmBD)
Sponsors
Shanghai Public Health Clinical Center
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Aged 18 and above; 2.ART naïve; 3.HIV positive individuals; 4.Confirmed Talaromycosis diagnosed by culture/microscopy;
Exclusion criteria
Exclusion criteria: 1.Pregnancy or lactating women; 2.Central nervous system involvement (assessed either through clinical manifestations or cerebrospinal fluid analysis); 3.Known allergy to AMB d/L-AMB, or the concomitant use of medications known to interact with AMB d/L-AMB; 4.Alanine aminotransferase or aspartate aminotransferase levels exceeding 400 U/L; 5.Absolute neutrophil count below 500/mm3; 6.Creatinine clearance below 30 mL/min (calculated using the Cockcroft and Gault equation); 7.Concurrent diagnosis of cryptococcal meningitis; 8.Concurrent treatment with rifampicin; 9.Previous treatment for talaromycosis lasting more than 48 hour;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the proportion of participants who achieve clinical resolution on day 14; | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to achieve a sterile blood culture;overall survival;time to clinical remission; | — |
Countries
China
Contacts
Public Contactshenyinzhong
Shanghai Public Health Clinical Center
Outcome results
None listed